- Home
- GSK vs WELL Comparison
GSK vs WELL Comparison
Compare GSK & WELL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GSK | WELL |
|---|---|---|
| Founded | 1715 | 1970 |
| Country | United Kingdom | United States |
| Employees | 66841 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Real Estate Investment Trusts |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 108.7B | 150.1B |
| IPO Year | N/A | 1994 |
Fundamental Metrics
Financial Performance| Metric | GSK | WELL |
|---|---|---|
| Price | $52.18 | $227.39 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 13 |
| Target Price | N/A | ★ $224.38 |
| AVG Volume (30 Days) | ★ 3.9M | 3.3M |
| Earning Date | 04-29-2026 | 04-28-2026 |
| Dividend Yield | ★ 3.40% | 1.40% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 1.02 |
| Revenue | N/A | ★ $10,838,034,000.00 |
| Revenue This Year | $6.99 | $28.56 |
| Revenue Next Year | $4.19 | $6.97 |
| P/E Ratio | ★ $32.75 | $218.93 |
| Revenue Growth | N/A | ★ 35.63 |
| 52 Week Low | $35.45 | $148.97 |
| 52 Week High | $61.70 | $224.47 |
Technical Indicators
Market Signals| Indicator | GSK | WELL |
|---|---|---|
| Relative Strength Index (RSI) | 53.30 | 66.22 |
| Support Level | $51.55 | $207.78 |
| Resistance Level | $53.45 | N/A |
| Average True Range (ATR) | 0.91 | 5.84 |
| MACD | 0.11 | 2.19 |
| Stochastic Oscillator | 58.87 | 98.43 |
Price Performance
Historical ComparisonAbout GSK GSK plc (Each representing two)
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, antiviral, and vaccines, and has been growing its presence in oncology and immunology, as well. GSK uses joint ventures to gain additional scale in certain markets like HIV.
About WELL Welltower Inc.
Welltower owns a diversified healthcare portfolio of 2,800 in-place properties spread across the senior housing, medical office, and skilled nursing/postacute care sectors. The portfolio includes over 900 properties in Canada and the United Kingdom as the company looks for additional investment opportunities in countries with mature healthcare systems that operate similarly to that of the United States.